Source: University of Sheffield, June 2025
Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period, according to new research led by the Universities of Sheffield.
- Reducing the length of immunotherapy treatment for an advanced skin cancer did not significantly diminish disease control when compared to giving treatments over a longer period
- Results from the five-year trial revealed that 80.2 per cent of patients who discontinued immunotherapy after 12 months continued to maintain disease control after a further 12 months
- Since joining the trial patient Jackie Summers, 77, has seen her tumour shrink to about half its size – despite receiving only 50 per cent of standard treatment